title: Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
abstract: It is known that solid tumors recruit new blood vessels to support tumor growth, but the molecular diversity of receptors in tumor angiogenic vessels might also be used clinically to develop better targeted therapy. In vivo phage display was used to identify peptides that specifically target tumor blood vessels. Several novel peptides were identified as being able to recognize tumor vasculature but not normal blood vessels in severe combined immunodeficiency (SCID) mice bearing human tumors. These tumor-homing peptides also bound to blood vessels in surgical specimens of various human cancers. The peptide-linked liposomes containing fluorescent substance were capable of translocating across the plasma membrane through endocytosis. With the conjugation of peptides and liposomal doxorubicin, the targeted drug delivery systems enhanced the therapeutic efficacy of the chemotherapeutic agent against human cancer xenografts by decreasing tumor angiogenesis and increasing cancer cell apoptosis. Furthermore, the peptide-mediated targeting liposomes improved the pharmacokinetics and pharmacodynamics of the drug they delivered compared with nontargeting liposomes or free drugs. Our results indicate that the tumor-homing peptides can be used specifically target tumor vasculature and have the potential to improve the systemic treatment of patients with solid tumors.
authors.affiliation: Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
authors.forename: De-Kuan
authors.initials: DK
authors.lastname: Chang
authors.forename: Chien-Yu
authors.initials: CY
authors.lastname: Chiu
authors.forename: Szu-Yao
authors.initials: SY
authors.lastname: Kuo
authors.forename: Wei-Chuan
authors.initials: WC
authors.lastname: Lin
authors.forename: Albert
authors.initials: A
authors.lastname: Lo
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Wang
authors.forename: Pi-Chun
authors.initials: PC
authors.lastname: Li
authors.forename: Han-Chung
authors.initials: HC
authors.lastname: Wu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D004705:Endocytosis; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D020287:In Situ Nick-End Labeling; D008081:Liposomes; D051379:Mice; D016513:Mice, SCID; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019151:Peptide Library; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D008081:Liposomes; D019151:Peptide Library; D010455:Peptides; D042461:Vascular Endothelial Growth Factor A; D004317:Doxorubicin